CAR-T-drug conjugate against solid tumor

Area of Science:

• Immunotherapy
• Oncology
• Drug Delivery

Background:

• Chimeric antigen receptor (CAR)-T cell therapy shows success in blood cancers but struggles with solid tumors due to poor infiltration and immunosuppressive tumor microenvironments (TME).
• Conventional combination therapies of CAR-T cells and chemotherapy often cause significant systemic toxicity.

Purpose of the Study:

• To introduce CAR-T-drug conjugates (CAR-T-D-C) as a novel dual-functional therapeutic strategy for solid tumors.
• To investigate the efficacy of CAR-T-D-C in overcoming TME challenges and enhancing CAR-T cell-mediated antitumor activity.

Main Methods:

• Development of CAR-T-D-C using click chemistry for precise conjugation of cytotoxic agents to antigen-specific CAR-T cells.
• Evaluation of CAR-T-D-C antitumor activity in diverse solid tumor models, including human xenografts and syngeneic models.
• Spatial transcriptomic analysis to assess CAR-T cell infiltration, activation, and immune response within the TME.

Main Results:

• CAR-T-D-C demonstrated robust antitumor activity across various solid tumor models.
• Spatial transcriptomics confirmed improved CAR-T cell infiltration and functional activation within the TME.
• CAR-T-D-C therapy enhanced immune cell infiltration, effector functions, antigen spreading, systemic immune responses, and overall anti-tumor immunity compared to conventional CAR-T therapy.

Conclusions:

• CAR-T-D-C represents a versatile 2-in-1 immunochemotherapy approach for solid tumors.
• This strategy effectively transforms the TME into an ally, enabling localized delivery of cytotoxic payloads and enhancing CAR-T therapy effectiveness.
• CAR-T-D-C combines the potency of small molecule drugs with the specificity of CAR-T cells, offering a promising new avenue for cancer treatment.